The present invention relates to azirine containing compounds useful as anti-angiogenesis agents and preparation thereof. Particularly the present invention relates to azirine containing compounds of formula I, Formula I wherein R.sub.1, R.sub.2 and R.sub.3 are same as defined in the description. The compounds of the present invention are with asymmetric centers this, they are mixture of enantiomers and mixture of diastereomers in some cases. The present invention includes the individual enantiomers and diastereomeric forms of the compound formula I besides the mixtures thereof.

##STR00001##

Described herein are new, selective modulators of the 5-HT.sub.7 receptor. These selective compounds can be useful for the treatment of CNS and non-CNS indications. Compounds described herein can be selective in targeting 5-HT.sub.7 receptors as compared to other receptors and/or by selective targeting 5-HT.sub.7 receptors expressed in certain tissues or organs, thereby effective selectivity through a particular partitioning profile of the 5-HT.sub.7 modulator.

##STR00001##

Described herein are new, selective modulators of the 5-HT.sub.7 receptor. These selective compounds can be useful for the treatment of CNS and non-CNS indications. Compounds described herein can be selective in targeting 5-HT.sub.7 receptors as compared to other receptors and/or by selective targeting 5-HT.sub.7 receptors expressed in certain tissues or organs, thereby effective selectivity through a particular partitioning profile of the 5-HT.sub.7 modulator.

##STR00001##

A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.

The present invention provides novel compounds of chemical formula 1, optical isomers of the compounds, or a pharmaceutically acceptable salts of the compounds, or the optical isomers. The compounds, isomers, and salts exhibits excellent activity as GLP-1 receptor agonists. Particularly, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used therapeutic agents for metabolic diseases. In addition, they exhibits excellent pharmacological safety for cardiovascular systems.

The present invention provides novel compounds of chemical formula 1, optical isomers of the compounds, or a pharmaceutically acceptable salts of the compounds, or the optical isomers. The compounds, isomers, and salts exhibits excellent activity as GLP-1 receptor agonists. Particularly, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used therapeutic agents for metabolic diseases. In addition, they exhibits excellent pharmacological safety for cardiovascular systems.

The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to sulfoximine-based inhibitors of ENPP1 and methods of their use for treating disease mediated by ENPP1.

The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds. ##STR00001##

The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds. ##STR00001##

The strigolactone receptor inhibitor for plants contains at least one kind of triazole urea compounds represented by the following formula (I) as an active ingredient. It can be applicable to an agricultural composition; a method for using the agricultural composition as, for example, a branching enhancer for plants; a germination inhibitor for Striga seeds, the germination inhibitor containing the triazole urea compound; and a novel triazole urea compound that is useful as a strigolactone receptor inhibitor for plants. In the formula, A represents a group represented by (A-1) or (A-2). R.sup.1 and R.sup.2 represent a hydrogen atom and so forth. R.sup.3 and R.sup.4 represent a hydrogen atom, an alkyl group having 1 to 20 carbon atoms, a cycloalkyl group having 3 to 20 carbon atoms, or an aryl group having 6 to 20 carbon atoms and so forth. R.sup.3 and R.sup.4 may form a ring together.

##STR00001##